

BMJ Open Going to extremes: the Goldilocks/Lagom principle and data distribution

Henry J Leese,¹ Thozhukat Sathyapalan,² Victoria Allgar,³ Daniel R Brison,⁴ Roger Sturmey ¹

To cite: Leese HJ, Sathyapalan T, Allgar V, *et al*. Going to extremes: the Goldilocks/Lagom principle and data distribution. *BMJ Open* 2019;**9**:e027767. doi:10.1136/bmjopen-2018-027767

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-027767>).

Received 06 November 2018

Revised 20 August 2019

Accepted 29 August 2019



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK

²Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK

³Hull York Medical School, Department of Health Sciences, University of York, York, UK

⁴Department of Reproductive Medicine, Manchester University NHS Foundation Trust, Manchester, UK

Correspondence to

Professor Henry J Leese;
henry.leese@hyms.ac.uk

ABSTRACT

Numerical data in biology and medicine are commonly presented as mean or median with error or confidence limits, to the exclusion of individual values. Analysis of our own and others' data indicates that this practice risks excluding 'Goldilocks' effects in which a biological variable falls within a range between 'too much' and 'too little' with a region between where its function is 'just right'; a concept captured by the Swedish term 'Lagom'. This was confirmed by a narrative search of the literature using the PubMed database, which revealed numerous relationships of biological and clinical phenomena of the Goldilocks/Lagom form including quantitative and qualitative examples from the health and social sciences. Some possible mechanisms underlying these phenomena are considered. We conclude that retrospective analysis of existing data will most likely reveal a vast number of such distributions to the benefit of medical understanding and clinical care and that a transparent approach of presenting each value within a dataset individually should be adopted to ensure a more complete evaluation of research studies in future.

INTRODUCTION

Numerical data in science and medicine have traditionally been presented as mean or median values with SEs or SDs. Such data commonly take the form of tables, bar graphs or line graphs. However, as Weissgerber *et al*¹ point out, this practice poses a problem since different distributions of data can lead to the same bar or line graph. This was well illustrated elegantly by George *et al*² who used illustrative data from a hypothetical experiment to examine the impact of three different cell lines on drug receptor activation and showed that a variety of distributions of individual data points can lead to similar bar graphs with the same mean ([figure 1](#)). This is because bar charts frequently do not convey major features of the dataset adequately. As [figure 1](#) makes clear, moving away from using bar charts to visualise the entire dataset is a necessary refinement that can increase the transparency and reporting of data.

The attention paid to individual variation in cellular and molecular biological and clinical studies is relatively recent, but has

been well-known for many years to ecologists, especially following the publication by Albert F Bennett,³ in 1987, of an influential article entitled: '*Inter-individual variability: an underutilized resource*'. Bennett, an ecological physiologist, pointed out that mean values with CIs about the mean, once published tend to '—take on a life of their own, and become the only point of analysis and comparison' to the exclusion of the individual values, and their potential significance. Bennett referred to this tendency as '*the tyranny of the Golden Mean*', and as an alternative, advocated the analysis of interindividual variability, that is, the full range of individual values, he considered could provide the observer with a greater interpretative repertoire.

In the time since Bennett's paper, there has been a movement away from the tyranny of the mean in many areas of biology, notably in ecology.⁴ Examples are provided by Stephen J Gould,⁵ who wrote an article on '*The median isn't the message*', Hayes and Jenkins⁶ on individual variation in mammals, and Lloyd-Smith⁷ on the spread of epidemics of human disease.

Our interest in interindividual variability arose particularly from research in which we have been involved on (1) the development and metabolism of single preimplantation mammalian embryos (DRB, HJL, RS) and (2) of glycaemic control in individual human subjects (TS).

Development and metabolism of single preimplantation embryos

Data which illustrate the value of distributions rather than mean or median values were provided by Guerif *et al*⁸ who measured the consumption of the essential nutrient, pyruvate, by single bovine preimplantation embryos at the zygote stage (1 cell fertilised egg; day 1 of development). The experiments revealed considerable heterogeneity between individual embryos such that it was possible to divide them prospectively into three groups—of 'high', 'intermediate' and 'low'




Figure 1 An illustrative example of a comparison of cell lines is described, which shows that bar charts do not give the reader adequate information on the variability and distribution of each sampled 'n'. The extent of activation of a receptor in three cell lines a, b and c under baseline (drug-naïve) conditions and following the addition of a drug is given in arbitrary units. The same datasets are presented in three different ways: (A) bar chart, (B) grouped column scatter plot with means and error and (C) before–after scatter plot. n=10 (ie, biological replicates and not technical replicates). In this example, error bars represent the SEM although authors should consider the sampling size and distribution of 'n' when choosing the most appropriate way of showing experimental error (eg, SD or CI).

pyruvate consumption at an early stage (day 2)—and track their subsequent development to the blastocyst stage, a critical developmental endpoint. These data indicated that intermediate values of pyruvate consumption correlated with viability (capacity to form a blastocyst), though with considerable overlap between the categories. Put another way, which takes account of this overlap, plotting individual values revealed the existence of an optimal 'range' of metabolic activity. This concept was developed in a follow-up paper⁹ in which we proposed that the optimal range was equivalent to a 'Goldilocks zone' or as it is known in Sweden, of 'Lagom', meaning 'just the right amount', in which embryos with maximum developmental potential are located.

Glycaemic control

Glycated haemoglobin (HbA_{1c}) is a marker of glycaemic control in patients with diabetes which is commonly used in clinical practice. Indeed, HbA_{1c} is the recommended test for diagnosing diabetes.¹⁰ There is an association between

the extent of high blood glucose as measured by HbA_{1c} and the risk of death and of macrovascular and microvascular disease in patients with type 2 diabetes (T2DM).¹¹ In the landmark UK Prospective Diabetes Study, intensive glycaemic control that aimed to achieve a HbA_{1c} level of 7% or below was associated with improved outcome in newly diagnosed patients with T2DM.¹² This finding was then extrapolated to all patients with T2DM, and as a result, lower HbA_{1c} levels were recommended for management of patients with T2DM. However, concerns arose as data from the Action to Control Cardiovascular Risk in Diabetes trial began to emerge showing *increased* all-cause mortality and cardiovascular mortality in the intensive treatment group who were treated with antihyperglycaemic agents aiming for a lower HbA_{1c} target of 6% compared with conventional antihyperglycaemic treatment in patients with T2DM aiming for HbA_{1c} of 7%–7.9%. These results led to early termination of the trial.¹³ Further studies^{14 15} have demonstrated that lower and higher mean HbA_{1c} values were associated with an increased risk of cardiovascular events and mortality suggesting a 'Goldilocks' or Lagom state of HbA_{1c} is the optimal.

Similar 'U' shaped associations with HbA_{1c} and all-cause mortality have also been shown for type 1 diabetes.¹⁶ Even in patients without diabetes, extremes of glycaemia as measured by HbA_{1c} are associated with adverse clinical outcomes including cardiovascular events and all-cause mortality. Similar increases in mortality in either extremes are seen with body weight, blood pressure, birth weight, cholesterol and other cardiovascular risk factors.

GOLDILOCKS AND LAGOM

The Goldilocks zone has been defined mathematically by Kohn and Melnick¹⁷ in the context of xenobiotic ligand binding to nuclear receptors as a 'Non-monotonic receptor-mediated dose-response curve' (NMDRC), and by Vandenberg¹⁸ in the context of endocrine disrupting chemicals as 'a response where the slope of the curve changes sign from positive to negative or vice versa somewhere along the range of doses examined'. These are valuable definitions because they can be applied to all non-linear distributions including U-shaped, inverted U-shaped, J-shaped, sigmoidal and reverse sigmoidal.

The U-shaped curve is probably the most widely observed. It usually refers to the nonlinear relationship between two variables, in particular, a dependent and an independent variable. Because many analytical methods assume an underlying linear relationship, systematic deviation from linearity can lead to bias in estimation of safe levels in exposure to nutrients, drugs or toxic agents (for a discussion, see section Mechanisms underlying the Goldilocks principle and what is Lagom and Vandenberg¹⁸).

HOW WIDESPREAD IS THE PRESENCE OF A GOLDILOCKS ZONE IN BIOLOGY AND MEDICINE?

We thought it might be instructive to discover how widely the notion of a Goldilocks zone is a feature of the wider

biological literature, especially as applied to medicine. A comprehensive search for information conducted on the *PubMed* database in early 2018 using the term ‘Goldilocks’ revealed 184 entries, all of which have been examined, together with the grey literature. Only articles in English language were selected. A selection of 43 of these publications has been presented (online supplementary appendix 1) as representative of the range of phenomena which invoke the Goldilocks concept in order to increase biological and clinical understanding. It should be emphasised that this is a narrative review rather than systematic review and no judgement on the quality of these studies or of those which have been omitted is implied.

Inspection of these examples reveals the wide range of biological and clinical phenomena in which Goldilocks zones have been found including the health and social sciences which can be qualitative rather than quantitative. It seems likely that a vast number remain to be discovered and that authors could, in a relatively simple manner, derive added value from their existing data by presenting distributions rather than median/mean values, and making raw data available to the research community via online repositories. This would allow systematic reanalysis by data scientists with an interest in the Goldilocks/Lagom concept.

MECHANISMS UNDERLYING THE GOLDILOCKS PRINCIPLE AND WHAT IS LAGOM

Mechanisms which are global in scope

We previously proposed an explanation that may account for Goldilocks/Lagom phenomena, derived from our work on energy efficiency in early mammalian embryo development⁹ which made use of an account of general aspects of biological optimisation by Johnson.¹⁹ The premise was that living things aim to function with the minimum input of energy, that is, with high energetic efficiency. To accomplish this will obviously require a threshold level of metabolic activity to ensure a given process proceeds in an optimum, yet efficient manner, while the upper limit will be set by the capacity to increase metabolism versus ‘*the energy parsimony in almost everything (living things) do*’.¹⁹ The Goldilocks/Lagom zone will obviously lie between these extremes. The boundaries will be set by homeostatic mechanisms at all levels of organisation. Such boundaries will be flexible in order to allow for the capacity to upregulate or downregulate metabolism in response to stress. Responses of these types have been usefully categorised by ecologists to distinguish (1) modest changes in metabolism (up or down within the *optimum* (Goldilocks/Lagom) range) from which the cell/organism can recover (the so-called *Pejus* range) and (2) extreme perturbation beyond the optimum which shifts metabolism irreversibly into a *Pessimum* range which is fatal (see figure 1 in the work of Sokolova).²⁰

Specific mechanisms

Specific mechanisms for the production of NMDRCs were well summarised by Vandenberg¹⁸ in terms of the effect of endocrine disrupting chemicals, notably Bisphenol A on cells in culture, whole organisms, laboratory animals and human populations. Interestingly, it was reported that NMDRCs were common, comprising 20%–30% of all studies examined, depending on the conditions; for example, in vivo versus in vitro. Mechanisms considered included cytotoxicity,²¹ inhibition of cell proliferation²²; hormone receptors produced versus degraded²³; cell and tissue-specific cofactors²⁴ and pharmacological effects. At the whole body level, examples of NMDRCs in nutrition are widespread, reflecting minimum requirements at the lower end of the distribution and toxicity at the higher, for example, vitamin A. Vandenberg¹⁸ concludes that ‘*strong evidence for Non-monotonic receptor-mediated dose-response curves*’—*question the current risk assessment practice where ‘safe’ levels are predicted from high dose exposures*’

CONCLUSION

There has long been a fixation in the biological and clinical research communities with presenting data solely as measures of dispersion (means and medians) and of central tendency (eg, SD and IQR). We believe that the retrospective analysis of existing data could reveal numerous potential relationships with a Goldilocks/Lagom pattern.

Interestingly, the editors of the British Journal of Pharmacology² ‘*will now require that, where possible, numerical data (whether categorical or continuous), particularly involving two sets or paired data, should be presented using scatter-plots, before-after graphs, and other forms in which each individual ‘n’ value is individually plotted, rather than using bar charts. Authors presenting data as bar charts should state that a scatter plot or before–after charts did not reveal unusual or interesting aspects of the data not obvious from the bar chart*’.

We believe the Journal should be complimented on this approach and urge all such journals to adopt it.

Contributors HJL: conceived the study, conducted literature searches and wrote the first draft. All authors then commented on subsequent drafts. VA: provided statistical advice. DRB: contributed to the initial concept and provided new material, as did RS who also prepared the manuscript for submission. TS: contributed to initial concept, provided new material and clinical expertise.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement statement No members of the public, nor patients, were involved in the preparation of this article.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.



ORCID iD

Roger Sturmey <http://orcid.org/0000-0003-4423-5058>

REFERENCES

- 1 Weissgerber TL, Milic NM, Winham SJ, *et al.* Beyond bar and line graphs: time for a new data presentation paradigm. *PLoS Biol* 2015;13:1–10.
- 2 George CH, Stanford SC, Alexander S, *et al.* Updating the guidelines for data transparency in the British Journal of Pharmacology - data sharing and the use of scatter plots instead of bar charts. *Br J Pharmacol* . 2017;174:2801–4.
- 3 Bennett AF. Interindividual variability: an underutilized resource. In: Feder ME, Bennett AF, Burggren WW, *et al.*, eds. *New directions in ecological physiology*. Cambridge University Press: Cambridge, UK, 1987: 147–69.
- 4 Roche DG, Careau V, Binning SA, *et al.* Demystifying animal 'personality' (or not): why individual variation matters to experimental biologists. *J Exp Biol* 2016;219:3832–43.
- 5 Gould SJ. The Median Isn't the Message. Available: https://people.umass.edu/biep540w/pdf/Stephen_Jay_Gould.pdf [Accessed 4 Oct 2018].
- 6 Hayes JP, Jenkins SH. Individual variation in mammals. *J Mammal* 1997;78:274–93.
- 7 Lloyd-Smith JO, Schreiber SJ, Kopp PE, *et al.* Superspreading and the effect of individual variation on disease emergence. *Nature* 2005;438:355–9.
- 8 Guerif F, McKeegan P, Leese HJ, *et al.* A simple approach for consumption and release (core) analysis of metabolic activity in single mammalian embryos. *PLoS One* 2013;8:e67834.
- 9 Leese HJ, Guerif F, Allgar V, *et al.* Biological optimization, the Goldilocks principle, and how much is *lagom* in the preimplantation embryo. *Mol Reprod Dev* 2016;83:748–54.
- 10 American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2011;34:S62–9.
- 11 Khaw K-T, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. *Curr Opin Lipidol* 2006;17:637–43.
- 12 Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet* 1998;352:837–53.
- 13 Duckworth W, Abraira C, Moritz T, *et al.* Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129–39.
- 14 Currie CJ, Peters JR, Tynan A, *et al.* Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. *Lancet* 2010;375:481–9.
- 15 Forbes A, Murrells T, Mulnier H, *et al.* Mean HbA, HbA variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. *Lancet Diabetes Endocrinol* 2018;6:476–86.
- 16 Schoenaker DAJM, Simon D, Chaturvedi N, *et al.* Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study. *J Clin Endocrinol Metab* 2014;99:800–7.
- 17 Kohn MC, Melnick RL. Biochemical origins of the non-monotonic receptor-mediated dose-response. *J Mol Endocrinol* 2002;29:113–23.
- 18 Vandenberg LN. Non-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol A as a case study. *Dose Response* 2014;12:259–76.
- 19 Johnson AT. Teaching the principle of biological optimization. *J Biol Eng* 2013;7:6.
- 20 Sokolova IM. Energy-Limited tolerance to stress as a conceptual framework to integrate the effects of multiple stressors. *Integr Comp Biol* 2013;53:597–608.
- 21 Welshons WV, Thayer KA, Judy BM, *et al.* Large effects from small exposures. I. mechanisms for endocrine-disrupting chemicals with estrogenic activity. *Environ Health Perspect* 2003;111:994–1006.
- 22 Soto AM, Sonnenschein C, Prechtl N, *et al.* Methods to screen estrogen-agonists and antagonists. *J Med Food* 1999;2:139–42.
- 23 Ismail A, Nawaz Z. Nuclear hormone receptor degradation and gene transcription: an update. *IUBMB Life* 2005;57:483–90.
- 24 Jeyakumar M, Webb P, Baxter JD, *et al.* Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. *Biochemistry* 2008;47:7465–76.